Dbv Technologies (DBV) | Stock Overview & Key Data
Dbv Technologies Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: €86.64 on October 9, 2017
Explore how other French stocks compare to their 52-week ranges: View FR Market 52-Week Insights
Key Statistics
Financial Highlights
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dbv Technologies
DBV
|
1.02B Large-cap | 12.32% | -4.78% | -7.80% | 2.24% | -2.45% | 89.31% | -17.08% | -70.89% | -94.37% | -62.38% | -62.38% |
|
Abivax SA
ABVX
|
7.61B Large-cap | -4.54% | -14.08% | -20.62% | -18.33% | -26.00% | 1,368.91% | 434.91% | 184.92% | 1,317.50% | 310.87% | 310.87% |
|
Nanobiotix
NANO
|
1.39B Large-cap | 3.58% | -27.34% | 8.48% | 64.63% | 67.58% | 587.64% | 529.63% | 150.41% | 87.73% | 393.55% | 393.55% |
|
TheraVet S.A
ALVET
|
N/A | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -89.74% | -98.11% | -99.02% | -99.02% | -99.02% | -99.02% |
|
Inventiva S.A
IVA
|
980.10M Mid-cap | -4.11% | -32.02% | -36.99% | -12.10% | -19.26% | 17.12% | -17.79% | -71.83% | -58.75% | -58.75% | -58.75% |
|
Medincell S.A
MEDCL
|
831.60M Mid-cap | -0.86% | 1.61% | 25.88% | 25.88% | 25.88% | 23.51% | 23.51% | 23.51% | 23.51% | 23.51% | 23.51% |
Ownership & Short Interest
Calculate Your Dbv Technologies Investment Returns
Long-Term Investment Performance Analysis
Dbv Technologies stock price in Jul 2016 was €64.40, A €1,000.00 lump sum investment in Dbv Technologies made 9 years ago would be worth approximately €49.53 today, representing a negative return of -95.05%. This translates to an annualized return (CAGR) of -26.16%.
9 Years 10 Months Investment Scenario (Jul 2016 - Jun 2026)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is DBV's 52-week high and low?
- In the last 52 weeks, Dbv Technologies reached a high of €4.50 (on December 17, 2025) and a low of €1.45 (on September 9, 2025).
- What is the market cap and P/E ratio for DBV?
- Curious about Dbv Technologies's size and valuation? Its market capitalization stands at 1.02B. When it comes to valuation, the P/E ratio (trailing twelve months) is -3.27, and the forward P/E (looking ahead) is -40.83.
- Does DBV pay dividends? If so, what's the yield?
- As for dividends, Dbv Technologies isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Dbv Technologies's main competitors or similar companies to consider before investing?
When looking at Dbv Technologies, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Abivax SA
ABVX7.61B Healthcare Biotechnology 1,368.91% 434.91% Nanobiotix
NANO1.39B Healthcare Biotechnology 587.64% 529.63% TheraVet S.A
ALVETN/A Healthcare Biotechnology -89.74% -98.11% Inventiva S.A
IVA980.10M Healthcare Biotechnology 17.12% -17.79% Medincell S.A
MEDCL831.60M Healthcare Biotechnology 23.51% 23.51% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Dbv Technologies S.A.? (e.g., ROE, Debt/Equity)
- To get a sense of Dbv Technologies's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -149.83%, the Debt to Equity ratio from the most recent quarter is 3.87, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for DBV?
- Looking at Dbv Technologies's growth, its revenue over the trailing twelve months (TTM) was €5M. Compared to the same quarter last year (YoY), quarterly revenue grew by 26.20%, and quarterly earnings saw a YoY growth of N/A.
- How much of DBV stock is held by insiders and institutions?
- Wondering who owns Dbv Technologies stock? Company insiders (like executives and directors) hold about 1.47% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 45.00%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.